Literature DB >> 22812498

Chemical macrocyclization of peptides fused to antibody Fc fragments.

Alessandro Angelini1, Philippe Diderich, Julia Morales-Sanfrutos, Sarah Thurnheer, David Hacker, Laure Menin, Christian Heinis.   

Abstract

To extend the plasma half-life of a bicyclic peptide antagonist, we chose to link it to the Fc fragment of the long-lived serum protein IgG1. Instead of chemically conjugating the entire bicyclic peptide, we recombinantly expressed its peptide moiety as a fusion protein to an Fc fragment and subsequently cyclized the peptide by chemically reacting its three cysteine residues with tris-(bromomethyl)benzene. This reaction was efficient and selective, yielding completely modified peptide fusion protein and no side products. After optimization of the linker and the Fc fragment format, the bicyclic peptide was fully functional as an inhibitor (K(i) = 76 nM) and showed an extended terminal half-life of 1.5 days in mice. The unexpectedly clean reaction makes chemical macrocyclization of peptide-Fc fusion proteins an attractive synthetic approach. Its good compatibility with the Fc fragment may lend the bromomethylbenzene-based chemistry also for the generation of antibody-drug conjugates.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22812498     DOI: 10.1021/bc300184m

Source DB:  PubMed          Journal:  Bioconjug Chem        ISSN: 1043-1802            Impact factor:   4.774


  7 in total

1.  Small cyclic agonists of iron regulatory hormone hepcidin.

Authors:  Kristine Chua; Eileen Fung; Ewa D Micewicz; Tomas Ganz; Elizabeta Nemeth; Piotr Ruchala
Journal:  Bioorg Med Chem Lett       Date:  2015-03-12       Impact factor: 2.823

Review 2.  Bicyclic Peptides as Next-Generation Therapeutics.

Authors:  Curran A Rhodes; Dehua Pei
Journal:  Chemistry       Date:  2017-07-27       Impact factor: 5.236

3.  Bridged Analogues for p53-Dependent Cancer Therapy Obtained by S-Alkylation.

Authors:  Ewa D Micewicz; Shantanu Sharma; Alan J Waring; Hai T Luong; William H McBride; Piotr Ruchala
Journal:  Int J Pept Res Ther       Date:  2015-08-19       Impact factor: 1.931

Review 4.  In vitro-engineered non-antibody protein therapeutics.

Authors:  Rudo Simeon; Zhilei Chen
Journal:  Protein Cell       Date:  2017-03-07       Impact factor: 14.870

5.  Directed evolution of broadly crossreactive chemokine-blocking antibodies efficacious in arthritis.

Authors:  Alessandro Angelini; Yoshishige Miyabe; Daniel Newsted; Byron H Kwan; Chie Miyabe; Ryan L Kelly; Misha N Jamy; Andrew D Luster; K Dane Wittrup
Journal:  Nat Commun       Date:  2018-04-13       Impact factor: 14.919

6.  Polyethyleneimine-based transient gene expression processes for suspension-adapted HEK-293E and CHO-DG44 cells.

Authors:  David L Hacker; Divor Kiseljak; Yashas Rajendra; Sarah Thurnheer; Lucia Baldi; Florian M Wurm
Journal:  Protein Expr Purif       Date:  2013-09-08       Impact factor: 1.650

7.  Blocking of the PD-1/PD-L1 interaction by a novel cyclic peptide inhibitor for cancer immunotherapy.

Authors:  Wenjie Zhai; Xiuman Zhou; Mingxia Zhai; Wanqiong Li; Yunhui Ran; Yixuan Sun; Jiangfeng Du; Wenshan Zhao; Lingxiao Xing; Yuanming Qi; Yanfeng Gao
Journal:  Sci China Life Sci       Date:  2020-07-28       Impact factor: 6.038

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.